Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06503458 · ClinicalTrials.gov registry record
A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants
A clinical trial, sponsored by Sanguine Biosciences.
- Terminated
- Registry status
- 52
- Enrollment target
NCT06503458 is a clinical trial that was terminated before completion, run by Sanguine Biosciences. The registered enrollment target is 52 participants.
The verdict
NCT06503458 was terminated before completion, sponsored by Sanguine Biosciences.
- TERMINATED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about painful crisis in people with Sickle Cell Disease. For this reason, Pfizer is conducting a study to understand how people with Sickle Cell Disease feel on a daily basis, treat these painful episodes including if they treat themselves at home or go to a doctor's office/emergency room, as well as the types of medications that are taken during these episodes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2024-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06503458
The ClinicalTrials.gov registry entry for NCT06503458 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06503458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06503458 about?
NCT06503458 is a clinical study titled "A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants". The purpose of this study is to learn more about painful crisis in people with Sickle Cell Disease. For this reason, Pfizer is conducting a study to understand how people with Sickle Cell Disease feel on a daily basis, treat these painful episodes including if they treat themselves at home or go to ...
What is the current status of trial NCT06503458?
This trial is currently terminated. The enrollment target is 52 participants. The study started on 2022-01-19. Estimated completion is 2024-04-10.
Who is sponsoring clinical trial NCT06503458?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.